<?xml version='1.0' encoding='utf-8'?>
<document id="25471740"><sentence text="Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin."><entity charOffset="32-37" id="DDI-PubMed.25471740.s1.e0" text="ethyl" /><entity charOffset="39-72" id="DDI-PubMed.25471740.s1.e1" text="eicosapentaenoic acid ethyl ester" /><entity charOffset="101-113" id="DDI-PubMed.25471740.s1.e2" text="atorvastatin" /><entity charOffset="61-72" id="DDI-PubMed.25471740.s1.e3" text="ethyl" /><pair ddi="false" e1="DDI-PubMed.25471740.s1.e0" e2="DDI-PubMed.25471740.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25471740.s1.e0" e2="DDI-PubMed.25471740.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25471740.s1.e0" e2="DDI-PubMed.25471740.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s1.e0" e2="DDI-PubMed.25471740.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s1.e1" e2="DDI-PubMed.25471740.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25471740.s1.e1" e2="DDI-PubMed.25471740.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s1.e1" e2="DDI-PubMed.25471740.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s1.e3" e2="DDI-PubMed.25471740.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s1.e3" e2="DDI-PubMed.25471740.s1.e2" /></sentence><sentence text="Icosapent ethyl is a high-purity prescription form of eicosapentaenoic acid ethyl ester approved as an adjunct to diet to reduce triglyceride levels in adult patients with triglyceride levels ≥500 mg/dL (≥5"><entity charOffset="10-15" id="DDI-PubMed.25471740.s2.e0" text="ethyl" /><entity charOffset="54-87" id="DDI-PubMed.25471740.s2.e1" text="eicosapentaenoic acid ethyl ester" /><entity charOffset="129-141" id="DDI-PubMed.25471740.s2.e2" text="triglyceride" /><entity charOffset="172-184" id="DDI-PubMed.25471740.s2.e3" text="triglyceride" /><entity charOffset="76-87" id="DDI-PubMed.25471740.s2.e4" text="ethyl" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e0" e2="DDI-PubMed.25471740.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e0" e2="DDI-PubMed.25471740.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e0" e2="DDI-PubMed.25471740.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e0" e2="DDI-PubMed.25471740.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e0" e2="DDI-PubMed.25471740.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e1" e2="DDI-PubMed.25471740.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e1" e2="DDI-PubMed.25471740.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e1" e2="DDI-PubMed.25471740.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e1" e2="DDI-PubMed.25471740.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e4" e2="DDI-PubMed.25471740.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e4" e2="DDI-PubMed.25471740.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e4" e2="DDI-PubMed.25471740.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e2" e2="DDI-PubMed.25471740.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s2.e2" e2="DDI-PubMed.25471740.s2.e3" /></sentence><sentence text="65 mmol/L)" /><sentence text=" The objective of this open-label, drug-drug interaction study was to examine the effects of icosapent ethyl on the steady-state pharmacokinetics of atorvastatin, a commonly prescribed medication in patients with dyslipidaemia"><entity charOffset="103-108" id="DDI-PubMed.25471740.s4.e0" text="ethyl" /><entity charOffset="149-161" id="DDI-PubMed.25471740.s4.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.25471740.s4.e0" e2="DDI-PubMed.25471740.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25471740.s4.e0" e2="DDI-PubMed.25471740.s4.e1" /></sentence><sentence text="" /><sentence text="Thirty healthy subjects received atorvastatin 80 mg/day on days 1-7, icosapent ethyl 4 g/day on days 8-28, and co-administration on days 29-35"><entity charOffset="79-90" id="DDI-PubMed.25471740.s6.e0" text="ethyl" /></sentence><sentence text=" Primary end-points were natural log-transformed maximum plasma concentration (C(max)) and area under the concentration-versus-time curve from 0 to 24 h (AUC(0-24)) for atorvastatin, 2-hydroxyatorvastatin, and 4-hydroxyatorvastatin with and without icosapent ethyl"><entity charOffset="169-181" id="DDI-PubMed.25471740.s7.e0" text="atorvastatin" /><entity charOffset="183-204" id="DDI-PubMed.25471740.s7.e1" text="2-hydroxyatorvastatin" /><entity charOffset="210-231" id="DDI-PubMed.25471740.s7.e2" text="4-hydroxyatorvastatin" /><entity charOffset="259-264" id="DDI-PubMed.25471740.s7.e3" text="ethyl" /><pair ddi="false" e1="DDI-PubMed.25471740.s7.e0" e2="DDI-PubMed.25471740.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25471740.s7.e0" e2="DDI-PubMed.25471740.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25471740.s7.e0" e2="DDI-PubMed.25471740.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s7.e0" e2="DDI-PubMed.25471740.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s7.e1" e2="DDI-PubMed.25471740.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25471740.s7.e1" e2="DDI-PubMed.25471740.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s7.e1" e2="DDI-PubMed.25471740.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s7.e2" e2="DDI-PubMed.25471740.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s7.e2" e2="DDI-PubMed.25471740.s7.e3" /></sentence><sentence text="" /><sentence text="Of the 30 subjects enrolled, 26 completed the study" /><sentence text=" The 90% confidence intervals for C(max) and AUC(0-24) least-squares geometric mean ratios were within the 0" /><sentence text="80-1" /><sentence text="25 bounds" /><sentence text=" Concomitant administration of icosapent ethyl and atorvastatin was safe and well tolerated and icosapent ethyl did not significantly change the steady state C(max) and AUC(0-24) of atorvastatin, 2-hydroxyatorvastatin, or 4-hydroxyatorvastatin"><entity charOffset="41-46" id="DDI-PubMed.25471740.s13.e0" text="ethyl" /><entity charOffset="51-63" id="DDI-PubMed.25471740.s13.e1" text="atorvastatin" /><entity charOffset="106-111" id="DDI-PubMed.25471740.s13.e2" text="ethyl" /><entity charOffset="182-194" id="DDI-PubMed.25471740.s13.e3" text="atorvastatin" /><entity charOffset="196-217" id="DDI-PubMed.25471740.s13.e4" text="2-hydroxyatorvastatin" /><entity charOffset="222-243" id="DDI-PubMed.25471740.s13.e5" text="4-hydroxyatorvastatin" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e0" e2="DDI-PubMed.25471740.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e0" e2="DDI-PubMed.25471740.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e0" e2="DDI-PubMed.25471740.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e0" e2="DDI-PubMed.25471740.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e0" e2="DDI-PubMed.25471740.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e0" e2="DDI-PubMed.25471740.s13.e5" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e1" e2="DDI-PubMed.25471740.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e1" e2="DDI-PubMed.25471740.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e1" e2="DDI-PubMed.25471740.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e1" e2="DDI-PubMed.25471740.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e1" e2="DDI-PubMed.25471740.s13.e5" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e2" e2="DDI-PubMed.25471740.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e2" e2="DDI-PubMed.25471740.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e2" e2="DDI-PubMed.25471740.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e2" e2="DDI-PubMed.25471740.s13.e5" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e3" e2="DDI-PubMed.25471740.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e3" e2="DDI-PubMed.25471740.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e3" e2="DDI-PubMed.25471740.s13.e5" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e4" e2="DDI-PubMed.25471740.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25471740.s13.e4" e2="DDI-PubMed.25471740.s13.e5" /></sentence><sentence text="" /><sentence text="At steady-state concentrations, icosapent ethyl did not have an effect on the pharmacokinetics of atorvastatin"><entity charOffset="42-47" id="DDI-PubMed.25471740.s15.e0" text="ethyl" /><entity charOffset="98-110" id="DDI-PubMed.25471740.s15.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.25471740.s15.e0" e2="DDI-PubMed.25471740.s15.e0" /><pair ddi="false" e1="DDI-PubMed.25471740.s15.e0" e2="DDI-PubMed.25471740.s15.e1" /></sentence><sentence text=" Co-administration of icosapent ethyl and atorvastatin was safe and well tolerated in healthy adult subjects"><entity charOffset="32-37" id="DDI-PubMed.25471740.s16.e0" text="ethyl" /><entity charOffset="42-54" id="DDI-PubMed.25471740.s16.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.25471740.s16.e0" e2="DDI-PubMed.25471740.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25471740.s16.e0" e2="DDI-PubMed.25471740.s16.e1" /></sentence><sentence text="" /></document>